AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations ...
A meta-analysis spanning more than 100 cardiology RCTs over three decades in more than a million patients offers a stern rebuke to the notion that nonfatal MI can serve as a surrogate for mortality, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results